First Bank & Trust Has $4.32 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

First Bank & Trust raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,575 shares of the biopharmaceutical company’s stock after purchasing an additional 1,570 shares during the period. Gilead Sciences accounts for about 0.8% of First Bank & Trust’s investment portfolio, making the stock its 23rd largest position. First Bank & Trust’s holdings in Gilead Sciences were worth $4,324,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in GILD. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Gilead Sciences by 12.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 323,011 shares of the biopharmaceutical company’s stock worth $27,081,000 after acquiring an additional 36,895 shares in the last quarter. NorthCrest Asset Manangement LLC boosted its position in Gilead Sciences by 1.1% during the third quarter. NorthCrest Asset Manangement LLC now owns 115,575 shares of the biopharmaceutical company’s stock worth $9,690,000 after purchasing an additional 1,252 shares during the period. Forsta AP Fonden grew its holdings in Gilead Sciences by 3.4% during the third quarter. Forsta AP Fonden now owns 397,400 shares of the biopharmaceutical company’s stock valued at $33,318,000 after purchasing an additional 12,900 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Gilead Sciences by 15.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 399,616 shares of the biopharmaceutical company’s stock valued at $33,412,000 after purchasing an additional 53,033 shares during the period. Finally, Outlook Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 5.1% during the 3rd quarter. Outlook Wealth Advisors LLC now owns 5,113 shares of the biopharmaceutical company’s stock worth $429,000 after buying an additional 247 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

GILD stock traded up $0.22 during trading on Friday, hitting $89.00. 5,734,995 shares of the stock traded hands, compared to its average volume of 7,043,532. The stock has a market cap of $110.88 billion, a price-to-earnings ratio of 247.22, a P/E/G ratio of 2.98 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $89.74. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The company has a 50 day simple moving average of $82.46 and a 200 day simple moving average of $73.42.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The company had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Equities analysts expect that Gilead Sciences, Inc. will post 3.78 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.46%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s payout ratio is 855.56%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, October 9th. Sanford C. Bernstein began coverage on Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target on the stock. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Finally, Barclays boosted their target price on shares of Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Ten analysts have rated the stock with a hold rating, eleven have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $86.85.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now owns 114,979 shares in the company, valued at $8,506,146.42. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,847 shares of company stock worth $3,033,340. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.